Cepheid to Webcast Upcoming Financial Pre... ( SUNNYVALE Calif. Nov. 7 /- Cephei...)

Cepheid to Webcast Upcoming Financial Presentations

Date:11/7/2008

SUNNYVALE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.

Credit Suisse Global Health Care Conference, Phoenix, AZ

Friday, November 14, 2008 at 8.00 a.m. Mountain Time

Piper Jaffray Health Care Conference, New York, NY

Tuesday, December 2, 2008 at 2.00 p.m. Eastern Time

Accessing Webcasts

To access the live webcasts for these events, please visit Cepheid's website at http://www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the presentation and will remain available for at least 90 days.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as ide
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
2. Cepheid Reports Third Quarter Revenue of $44.9 Million
3. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
4. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
5. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
6. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
7. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
10. Cepheid Reports Second Quarter Revenue of $42.1 Million
11. Cepheid to Webcast Analyst Event

Post Your Comments:

Cepheid to Webcast Upcoming Financial Pre...( SUNNYVALE Calif. Nov. 7 /- Cephei...)